Madrigal Pharmaceuticals (MDGL)
(Delayed Data from NSDQ)
$252.74 USD
+4.06 (1.63%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $253.00 +0.26 (0.10%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Company Summary
Based in West Conshohocken, PA, Madrigal Pharmaceuticals, Inc. is a commercial-stage company focused on developing novel therapeutics for patients with NASH. This serious liver disease can lead to cirrhosis, liver failure and premature mortality. NASH is also known as metabolic dysfunction-associated steatohepatitis (MASH).
In March 2024, Madrigal’s lead candidate, Rezdiffra (resmetirom), became the first and only FDA-approved therapy for the treatment of adult patients with noncirrhotic NASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), in conjunction with diet and exercise. The drug was approved under the FDA&...
Company Summary
Based in West Conshohocken, PA, Madrigal Pharmaceuticals, Inc. is a commercial-stage company focused on developing novel therapeutics for patients with NASH. This serious liver disease can lead to cirrhosis, liver failure and premature mortality. NASH is also known as metabolic dysfunction-associated steatohepatitis (MASH).
In March 2024, Madrigal’s lead candidate, Rezdiffra (resmetirom), became the first and only FDA-approved therapy for the treatment of adult patients with noncirrhotic NASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), in conjunction with diet and exercise. The drug was approved under the FDA’s accelerated pathway and was commercially launched in the United States in April 2024. Rezdiffra is a once-daily, oral and liver-directed THR-β agonist designed to target key underlying causes of NASH.
A regulatory application seeking the approval of resmetirom for the same indication is also currently under review in the EU.
The company’s clinical-stage pipeline currently comprises several late-stage studies evaluating expanded use of Rezdiffra for NASH, including the pivotal MAESTRO-NASH biopsy study in patients with significant fibrosis, the MAESTRO-NASH Outcomes study in patients with NASH with compensated cirrhosis and the MAESTRO-NAFLD-1 open-label extension (OLE) safety study.
In the absence of ongoing collaboration agreements, Madrigal’s only contributor to the top line is Rezdiffra sales. The company did not record any revenues in the first quarter of 2024 as the drug had not been commercially launched yet.
The company is expected to record initial sales figures for Rezdiffra from the second quarter onward. Madrigal did not recognize any revenues in 2023 or the year before.
General Information
Madrigal Pharmaceuticals, Inc
200 BARR HARBOR DRIVE SUITE 200
WEST CONSHOHOCKEN, PA 19428
Phone: 267-824-2827
Fax: 781-274-8228
Web: http://www.madrigalpharma.com
Email: ir@madrigalpharma.com
Industry | Medical - Drugs |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 6/30/2024 |
Exp Earnings Date | 11/4/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | -7.58 |
Current Year EPS Consensus Estimate | -27.67 |
Estimated Long-Term EPS Growth Rate | NA |
Exp Earnings Date | 11/4/2024 |
Price and Volume Information
Zacks Rank | ![]() |
Yesterday's Close | 248.68 |
52 Week High | 299.98 |
52 Week Low | 119.76 |
Beta | NA |
20 Day Moving Average | 310,611.34 |
Target Price Consensus | 350.79 |
4 Week | -10.84 |
12 Week | 12.08 |
YTD | 9.23 |
4 Week | -14.56 |
12 Week | 4.15 |
YTD | -7.97 |
Shares Outstanding (millions) | 21.71 |
Market Capitalization (millions) | 5,487.74 |
Short Ratio | NA |
Last Split Date | 7/25/2016 |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | NA |
Change in Payout Ratio | NA |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | NA |
Trailing 12 Months | NA |
PEG Ratio | NA |
vs. Previous Year | -51.39% |
vs. Previous Quarter | 3.79% |
vs. Previous Year | NA% |
vs. Previous Quarter | NA% |
Price/Book | 6.40 |
Price/Cash Flow | NA |
Price / Sales | NA |
6/30/24 | -95.61 |
3/31/24 | -128.60 |
12/31/23 | -219.39 |
6/30/24 | -66.71 |
3/31/24 | -78.52 |
12/31/23 | -98.75 |
6/30/24 | 8.72 |
3/31/24 | 9.39 |
12/31/23 | 5.38 |
6/30/24 | 8.67 |
3/31/24 | 9.39 |
12/31/23 | 5.38 |
6/30/24 | NA |
3/31/24 | NA |
12/31/23 | NA |
6/30/24 | NA |
3/31/24 | NA |
12/31/23 | NA |
6/30/24 | -3,487.13 |
3/31/24 | NA |
12/31/23 | NA |
6/30/24 | 39.48 |
3/31/24 | 39.97 |
12/31/23 | 20.53 |
6/30/24 | 0.32 |
3/31/24 | 0.00 |
12/31/23 | NA |
6/30/24 | 0.14 |
3/31/24 | 0.14 |
12/31/23 | 0.28 |
6/30/24 | 11.98 |
3/31/24 | 12.01 |
12/31/23 | 22.17 |